^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

ER negative + HER-2 negative

i
Other names: ESR1, Era, ESR, NR3A1, ER, ER beta, ERBB2, CD340, HER-2, HER2, NEU, NGL, V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2
Entrez ID:
over1year
Prognosis and effectiveness of chemotherapy for medullary breast carcinoma. (PubMed, Breast Cancer Res Treat)
In ER-negative and HER2-negative MedBC, the risk of recurrence and death was significantly lower than that of IDC, about half. Postoperative chemotherapy reduced recurrence and mortality. ER-positive and HER2-negative MedBC may have a lower risk of recurrence compared to IDC.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
ER positive • HER-2 negative • ER negative • ER positive + HER-2 negative • ER negative + HER-2 negative
2years
CADENCE: Neoadjuvant Carboplatin and Docetaxel in Triple Negative Breast Cancer (clinicaltrials.gov)
P2, N=25, Active, not recruiting, Mothaffar Rimawi | Trial completion date: Sep 2021 --> Sep 2024
Trial completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative • ER negative • PGR positive • ER negative + HER-2 negative
|
carboplatin • docetaxel
2years
The Association Between Hormone Receptor Status and End-of-Life Care Among Patients With Metastatic Breast Cancer. (PubMed, Clin J Oncol Nurs)
Patients with ER-positive MBC had greater odds of receiving quality end-of-life care than those with ER-negative MBC. HER2 status was not associated with differences in the quality of end-of-life care.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
ER positive • HER-2 negative • ER negative • ER negative + HER-2 negative